The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits

Brain Research

Volumn 1303, Issue , 2009, Pages 144-150

  Lapchak, Paul A ^a   Han, Moon Ku ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Neuroscience Center   (South Korea)

Author keywords

Intracerebral hemorrhage; Ischemic stroke; Neuroprotection; Translational science

Indexed keywords

SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; EXPERIMENTAL RABBIT; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACRANIAL EMBOLISM; MALE; PREOPERATIVE CARE; RABBITS; RATS; SIMVASTATIN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

ORYCTOLAGUS CUNICULUS;

EID: 72049117774     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.064     Document Type: Article

References (49)

1. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., Sillesen H., Simunovic L., Szarek M., Welch K.M., and Zivin J.A. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355 (2006) 549-559
2. Bays H. Statin safety: an overview and assessment of the data-2005. Am. J. Cardiol. 97 (2006) 6C-26C
3. Chmielewski M., Zdrojewski Z., and Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann. Transplant. 7 (2002) 6-10
4. Cimino M., Balduini W., Carloni S., Gelosa P., Guerrini U., Tremoli E., and Sironi L. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology 26 (2005) 929-933
5. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84 (1999) 413-428
6. Delanty N., and Vaughan C.J. Vascular effects of statins in stroke. Stroke 28 (1997) 2315-2320
7. Endres M. Statins and stroke. J. Cereb. Blood Flow Metab. 25 (2005) 1093-1110
8. Goldstein L.B., Amarenco P., Szarek M., Callahan III A., Hennerici M., Sillesen H., Zivin J.A., and Welch K.M. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70 (2008) 2364-2370
9. Hacke W., Kaste M., Bluhmki E., Brozman M., Davalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., and Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359 (2008) 1317-1329
10. Halcox J.P., and Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109 (2004) II42-II48
11. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 278 (1997) 313-321
12. Hess D.C., Demchuk A.M., Brass L.M., and Yatsu F.M. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology 54 (2000) 790-796
13. Ingall T. Stroke-incidence, mortality, morbidity and risk. J. Insur. Med. 36 (2004) 143-152
14. Jung K.H., Chu K., Jeong S.W., Han S.Y., Lee S.T., Kim J.Y., Kim M., and Roh J.K. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 35 (2004) 1744-1749
15. Karki K., Knight R.A., Han Y., Yang D., Zhang J., Ledbetter K.A., Chopp M., and Seyfried D.M. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke 40 10 (2009) 3384-3389
16. Kashyap M.L. Cholesterol and atherosclerosis: a contemporary perspective. Ann. Acad. Med. Singap. 26 (1997) 517-523
17. Kerz T., Victor A., Beyer C., Trapp I., Heid F., and Reisch R. A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurol. Res. 30 (2008) 893-897
18. Kolovou G.D., Katerina A., Ioannis V., and Cokkinos D.V. Simvastatin: two decades in a circle. Cardiovasc. Ther. 26 (2008) 166-178
19. Kramer A.H., Gurka M.J., Nathan B., Dumont A.S., Kassell N.F., and Bleck T.P. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery 62 (2008) 422-427 discussion 427-30
20. Lapchak P.A. Tumor necrosis factor-alpha is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits. Brain Res. 1167 (2007) 123-128
21. Lapchak P.A., Chapman D.F., and Zivin J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31 (2000) 3034-3040
22. Lapchak P.A., Araujo D.M., Song D., Wei J., Purdy R., and Zivin J.A. Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 33 (2002) 1665-1670
23. Lapchak P.A., Han M.K., Salgado K.F., Streeter J., and Zivin J.A. Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits. Stroke 39 (2008) 3073-3078
24. Liao J.K. Statins and ischemic stroke. Atheroscler. Suppl. 3 (2002) 21-25
25. Liu X.S., Zhang Z.G., Zhang L., Morris D.C., Kapke A., Lu M., and Chopp M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J. Cereb. Blood Flow Metab. 26 (2006) 787-796
26. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., Ford E., Furie K., Go A., Greenlund K., Haase N., Hailpern S., Ho M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M., Meigs J., Mozaffarian D., Nichol G., O'Donnell C., Roger V., Rosamond W., Sacco R., Sorlie P., Stafford R., Steinberger J., Thom T., Wasserthiel-Smoller S., Wong N., Wylie-Rosett J., and Hong Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) e21-181
27. Lo E.H., Wang X., and Cuzner M.L. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69 (2002) 1-9
28. Lyden P.D., Zivin J.A., Clark W.A., Madden K., Sasse K.C., Mazzarella V.A., Terry R.D., and Press G.A. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology 39 (1989) 703
29. Meier N., Nedeltchev K., Brekenfeld C., Galimanis A., Fischer U., Findling O., Remonda L., Schroth G., Mattle H.P., and Arnold M. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke 40 (2009) 1729-1737
30. Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Rev. Neurother. 5 (2005) 211-221
31. Moonis M., and Fisher M. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Rev. Neurother. 4 (2004) 241-247
32. Naval N.S., Abdelhak T.A., Zeballos P., Urrunaga N., Mirski M.A., and Carhuapoma J.R. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit. Care 8 (2008) 6-12
33. Pfefferkorn T., and Rosenberg G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34 (2003) 2025-2030
34. Rosenberg G.A., Cunningham L.A., Wallace J., Alexander S., Estrada E.Y., Grossetete M., Razhagi A., Miller K., and Gearing A. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 893 (2001) 104-112
35. Rutishauser J. The role of statins in clinical medicine-LDL-cholesterol lowering and beyond. Swiss Med. Wkly. 136 (2006) 41-49
36. Schmeer C., Kretz A., and Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor. Neurol. Neurosci. 24 (2006) 79-95
37. Seyfried D., Han Y., Lu D., Chen J., Bydon A., and Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J. Neurosurg. 101 (2004) 104-107
38. Spatz E.S., Canavan M.E., and Desai M.M. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ. Cardiovasc. Qual. Outcomes 2 (2009) 41-48
39. Sugawara T., Ayer R., Jadhav V., Chen W., Tsubokawa T., and Zhang J.H. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J. Neurosci. Res. 86 (2008) 3635-3643
40. Sugawara T., Jadhav V., Ayer R., and Zhang J. Simvastatin attenuates cerebral vasospasm and improves outcomes by upregulation of PI3K/Akt pathway in a rat model of subarachnoid hemorrhage. Acta Neurochir. Suppl. 102 (2008) 391-394
41. Trinkl A., Vosko M.R., Wunderlich N., Dichgans M., and Hamann G.F. Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusion. Eur. J. Neurosci. 24 (2006) 520-526
42. Uyttenboogaart M., Koch M.W., Koopman K., Vroomen P.C., Luijckx G.J., and De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J. Neurol. 255 (2008) 875-880
43. Vergouwen M.D., Meijers J.C., Geskus R.B., Coert B.A., Horn J., Stroes E.S., van der Poll T., Vermeulen M., and Roos Y.B. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J. Cereb. Blood Flow Metab. 29 8 (2009) 1444-1453
44. Vivancos-Mora J., and Gil-Nunez A.C. Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc. Dis. 20 Suppl. 2 (2005) 53-67
45. Waldman A., and Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 63 (2003) 139-152
46. Wang S., Lee S.R., Guo S.Z., Kim W.J., Montaner J., Wang X., and Lo E.H. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 37 (2006) 1910-1912
47. Werner N., Nickenig G., and Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97 (2002) 105-116
48. Wu L., Zhao L., Zheng Q., Shang F., Wang X., Wang L., and Lang B. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Mol. Cell Biochem. 284 (2006) 65-71
49. Zhang L., Zhang Z.G., Ding G.L., Jiang Q., Liu X., Meng H., Hozeska A., Zhang C., Li L., Morris D., Zhang R.L., Lu M., and Chopp M. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112 (2005) 3486-3494